Stockholm (HedgeNordic) – Susanna Urdmark, co-head and senior portfolio manager of long-biased long/short equity fund Rhenman Healthcare Equity L/S, is leaving Rhenman & Partners after a six-year tenure with the firm. She will be stepping down from her role during the summer to pursue other opportunities.

“Susanna Urdmark, Co-head and senior fund manager, has decided to leave the firm after six years to pursue other opportunities,” announces the team at Rhenman & Partners. “I would like to thank Susanna for her important contribution to the fund’s successful development, and wish her all the best on the journey ahead,” says Henrik Rhenman, the founder and CIO of Rhenman & Partners. Rhenman has co-managed Rhenman Healthcare Equity L/S alongside Urdmark since she joined the asset manager in mid-2017.

“I would like to thank Susanna for her important contribution to the fund’s successful development, and wish her all the best on the journey ahead.”

Prior to joining Rhenman & Partners in May 2017, Susanna Urdmark held the position of CFO of Bluefish Pharmaceuticals, a Swedish pharmaceutical company that manufactures medical generics, for nine and a half years. She also served as a portfolio manager of Handelsbanken Asset Management’s Global Healthcare Fund and worked as a sell-side senior equity analyst covering Nordic pharma and biotech companies for Handelsbanken Capital Markets. She started her career in corporate finance at Carnegie Investment Bank before pursuing an MA in Medical Sciences at Boston University School of Medicine.

Rhenman Healthcare Equity L/S, a healthcare-focused long-biased equity hedge fund launched in mid-2009, has achieved an annualized return of 16.2 percent. With €827 million in assets under management, the fund will continue to be managed by a team of four led by Henrik Rhenman, who is supported by portfolio manager Kaspar Hållsten, as well as analysts Hugo Schmidt and Amennai Beyeen.